Generics would be shut out of PTAB under Hatch amendment
The Hatch-Waxman Integrity Act of 2018 would require a generic manufacturer wishing to challenge a brand-name drug patent to choose between Hatch-Waxman litigation and IPR, which one observer describes as a “Hobson’s choice”
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: